The Omicron variant, which is spreading far faster than previous versions of the coronavirus, is not likely to help countries achieve so-called herd immunity against COVID-19 – in which enough people become immune to the virus that it can no longer spread – leading disease experts say.
If you are not happy with the results below please do another search
50 search results for:
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and White House chief medical advisor, said they expect the U.S. Food and Drug Administration will authorize the Pfizer-BioNTech vaccine for children under the age of 5 years in the next month.
A small preliminary laboratory study has shown that levels of Omicron-neutralizing antibodies of people vaccinated with Russia’s Sputnik V vaccine did not decline as much as those who had Pfizer shots.
Nearly 30 generic drugmakers in Asia, Africa and the Middle East will make cheap versions of Merck & Co’s COVID-19 pill, under a landmark U.N.-backed deal to give poorer nations wider access to a drug seen as a weapon in fighting the pandemic.
The Biden administration is preparing for future variants of COVID-19, White House chief of Staff Ron Klain told MSNBC in an interview that aired on January 20 as the Omicron-related wave of cases appeared to be easing in parts of the United States.
Zymeworks provided a corporate update that included a string of clinical trial news. Additionally, 10 members of Zymeworks’ senior management team are leaving the clinical-stage biopharmaceutical company and the employee headcount will be cut by at least 25 percent by the end of 2022.
Belgium’s UCB is acquiring California-based Zogenix, a company focused on rare diseases, in a deal valued up to €1.7 billion ($1.9 billion).
After a rejection from GlaxoSmithKline on a proposed £50 billion (about $68 billion) buyout of GSK’s consumer healthcare business, Unilever announced that the global consumer product giant will not increase its bid.
More than 1.2 million people died in 2019 from infections caused by bacteria resistant to multiple antibiotics, higher than HIV/AIDS or malaria, according to a new report published on January 20.
Engitix Therapeutics raised $54 million in Series A financing. Engitix plans to use the money to boost the company’s drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.